26th March 2020
Profil, a CRO (contract research organisation) specialised in early phase clinical trials, is offering up to 80 beds in two up-to date research clinics as well as regulatory advice and early phase trial support, to companies developing vaccines against COVID-19
As one of the leading phase 1 units in Europe, Profil can offer experience with Europe’s regulatory landscape and help conduct early phase trials in their two clinics based in Frankfurt and Düsseldorf. At the time of this post, they have 80 beds available.
With experience performing hundreds of early phase clinical trials including dozens of first-in-human studies, the team has investigators with vast experience in vaccine studies.
The organisation is reaching out to companies developing candidate vaccines against COVID-19 and offering their help with testing these developments in FIH-studies at attractive conditions in healthy people.
They are particularly committed to fighting against a further fast spread of COVID-19 as people with diabetes, where their expertise lies, are reported to have an increased risk of developing the infection and a higher risk for a severe disease course and mortality.
ASK: Research contributors needed for CON-VICE study
University of Luxembourg needs European researchers to get in touch
OFFER: Funding available for COVID-19 research
Fondation Air Liquide are looking to fund European projects
ASK: Supporting the immunocompromised
Partners sought to advance neutralising antibody